SCHEMBL7162436

SCHEMBL7162436

CN1OCC(=O)N(C(c2ccccc2)c2ccccc2)C1=S

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.37
▸ NPSR1 Q6W5P4 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ CHRM2 P08172 2/20 0.37
▸ ADRA2A P08913 2/20 0.37
▸ CHRM1 P11229 2/20 0.37
▸ DRD1 P21728 2/20 0.37
▸ DRD3 P35462 2/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ OPRM1 P35372 2/20 0.37
▸ CHRM4 P08173 1/20 0.37
▸ CHRM5 P08912 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CHRM3 P20309 1/20 0.37
▸ ADRA1D P25100 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8675744 0.76 OPRM1 (0.40) MAPTNPSR1LMNAKDM4ECHRM2
SCHEMBL7164266 0.67 FAAH (0.49) MAPTALDH1A1L3MBTL1
SCHEMBL7164530 0.66 MGLL (0.48) MAPTNPSR1LMNAKMT2AMEN1
SCHEMBL6929886 0.64 ALDH1A1 (0.43) MAPTNPSR1LMNAKDM4ECHRM2
SCHEMBL9819292 0.64 CHRM2 (0.43) CHRM2ADRA2ACHRM1DRD1DRD3
SCHEMBL16118505 0.61 ALDH1A1 (0.46) MAPTCYP2D6KMT2AALDH1A1HPGD
SCHEMBL5164869 0.61 ALDH1A1 (0.46) MAPTCYP2D6KMT2AALDH1A1HPGD
SCHEMBL2175411 0.61 MGLL (0.44) MAPTNPSR1LMNAKDM4ECHRM2
SCHEMBL17360649 0.59 KMT2A (0.41) MAPTNPSR1LMNAKDM4ECHRM2
SCHEMBL11650115 0.59 MEN1 (0.42) MAPTNPSR1LMNAKDM4ECYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562814-B2 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives WYETH 2003-05-13 — — US claimed
US-20020061883-A1 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives AMERICAN HOME PRODUCTS CORPORATION 2002-05-23 — — US claimed
WO-2002028845-A1 3-THIOXO-[1,2,4]-OXADIAZINAN-5-ONE AND THEIR USE AS ANTI-ANTHEROSCLEROTIC AGENTS WYETH (US) 2002-04-11 — — WO claimed
US-6562814-B2 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives WYETH 2003-05-13 — — US disclosed
US-20020061883-A1 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives AMERICAN HOME PRODUCTS CORPORATION 2002-05-23 — — US disclosed
WO-2002028845-A1 3-THIOXO-[1,2,4]-OXADIAZINAN-5-ONE AND THEIR USE AS ANTI-ANTHEROSCLEROTIC AGENTS WYETH (US) 2002-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061883-A1 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives AHR, PAOX, PPARA MAPT 4600/4885NPSR1 1207/4885LMNA 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback